Clinical Scorecard: Reassessing Genetic Variants: A Comprehensive Review
At a Glance
Category
Detail
Condition
Genetic variant classification and reclassification in hereditary disorders
Key Mechanisms
Reassessment of genetic variant pathogenicity using accumulating evidence including population data, functional studies, computational predictions, segregation analyses, and literature review
Target Population
Patients undergoing genetic testing for hereditary conditions, primarily in oncology, cardiology, and rare diseases
Care Setting
Clinical genetics and genomic medicine settings integrating next-generation sequencing and genetic testing
Key Highlights
Variant reclassification rates vary widely from 3.6% to 83.6% depending on study conditions and variant types.
Nearly half of studies focus on variants of uncertain significance (VUS), highlighting challenges in initial classification.
Reclassification methods include literature review, functional assays, in silico pathogenicity prediction, segregation analysis, and machine learning tools.
Guideline-Based Recommendations
Diagnosis
Use ACMG/AMP 2015 guidelines for initial variant classification into benign, likely benign, VUS, likely pathogenic, and pathogenic categories.
Collect evidence from multiple sources including population frequency, computational data, functional studies, segregation, and literature.
Management
Recognize that variant classification is dynamic and requires periodic reassessment as new evidence emerges.
Incorporate routine reinterpretation and reanalysis protocols to update variant classifications.
Communicate reclassification outcomes effectively to patients and healthcare providers.
Monitoring & Follow-up
Monitor variant classifications over time to identify changes impacting clinical management.
Establish structured processes for recontacting patients when variant reclassification affects clinical care.
Risks
Potential misclassification due to limited initial evidence can affect diagnosis and treatment decisions.
Lack of standardized guidelines for reclassification and recontact may lead to inconsistent patient management.
Patient & Prescribing Data
Patients with genetic variants identified through clinical genetic testing, especially in oncology, cardiology, and rare diseases
Accurate and updated variant classification informs molecular diagnosis, prognosis, therapeutic decisions, preventive strategies, and risk assessment for relatives
Clinical Best Practices
Apply ACMG/AMP guidelines rigorously for variant classification and acknowledge inherent uncertainties.
Implement systematic variant reanalysis using multidisciplinary evidence including functional and computational data.
Develop consensus protocols for variant reclassification, patient recontact, and communication of updated results.
Focus research and clinical efforts on underrepresented fields such as endocrinology and obesity-related genetic variants.
Utilize machine learning and bioinformatics tools to enhance variant interpretation accuracy.
